ABVD chemotherapy scheme at day 1 and 8 for treatment of primary Hodgkin's lymphomas
10.3760/cma.j.issn.0578-1426.2009.03.004
- VernacularTitle:ABVD第1、8天用药方案治疗初治霍奇金淋巴瘤疗效观察
- Author:
Yufu LI
;
Yanli ZHANG
;
Bojun FANG
;
Jianwei DU
;
Xiaodong LU
;
Lina ZHANG
;
Xinghu ZHU
;
Xudong WEI
;
Yongping SONG
;
Jichang LI
- Publication Type:Journal Article
- Keywords:
Hodgkin disease;
Antineoplastic combined chemotherapy protocols;
Disease-free survival
- From:
Chinese Journal of Internal Medicine
2009;48(3):186-188
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of adriamycin, bleomyein, vincristine and dacarbazinum (ABVD) chemotherapy scheme executed at day I and day 8 for primary Hodgkin's lymphomas (HL). Methods 62 patients with primary HL in stages Ⅱ-Ⅳ treated in our department from October 2005 to October 2006 were divided into group A and B at random with 31 patients in each group. The patients in group A received ABVD chemotherapy scheme executed at day 1 and day 8 for 6-8 cycles. The patients in group B received ABVD chemotherapy scheme executed at day 1 and day 15 for 6-8 cycles. The patients of the groups received radiotherapy by the same doctor after chemotherapy according to the patients condition and the radiotherapy regimens were not affected by the grouping. Results The complete remission rate (CR)in group A after chemotherapy was 90. 3% (28/31);the one-year and two-year disease free survival (DFS) rates were 87. 1% (27/31) and 80.0% (20/25)respectively. The CR rate in group B after chemotherapy was 83.9% (26/31);the one-year and two-year DFS rates were 80. 6% (25/31)and 72. 0% (18/25) respectively. The discrepancy of CR rates and the one-year and two-year DFS rates between the two groups was not significant (P>0.05). The incidences of therapeutic side effecte such as myocardial iscnemia grade Ⅲ-Ⅳ liver function impair-ment,pulmonary fibrosis and serious marrow inhibition between the two groups were not significant too (P > 0.05). Average chemotherapy period for the patients in group A was 159 days; it was 69 days shorter than that in group B. Conclusion The CR rate,1-year DFS rate and 2-year DFS rate of ABVD chemotherapy scheme executed at day 1 and 8 are similar to those of ABVD chemotherapy scheme executed at day Ⅰ and 15 for primary HL in stages Ⅱ-Ⅳ. The side-effects of chemoterapy between group A and B are similar too. The chemotherapy period in group A is shortened significantly.
